
Abstract
It has been suggested that natalizumab-associated progressive multifocal leukoencephalopathy may be prevented by structured interruptions of treatment.
Evidence supporting such a drug holiday is not yet available.
Here we present initial observations in 10 multiple sclerosis patients who were stringently monitored up to 6 months after discontinuation of the infusions.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1768